Aerpio Pharmaceuticals is a biotechnology business based in the US. Aerpio Pharmaceuticals shares (ARPO) are listed on the NASDAQ and all prices are listed in US Dollars. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.70 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $31.63 |
| 200-day moving average | $25.85 |
| Wall St. target price | $22.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.41 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.7 from 2021-05-28
| 1 week (2024-07-14) | N/A |
|---|---|
| 1 month (2024-06-21) | N/A |
| 3 months (2024-04-21) | N/A |
| 6 months (2024-01-21) | N/A |
| 1 year (2023-07-21) | N/A |
|---|---|
| 2 years (2022-07-21) | N/A |
| 3 years (2021-07-23) | 2.07 |
| 5 years (2019-07-25) | 109.88% |
| Gross profit TTM | $15 million |
|---|---|
| Return on assets TTM | -31.02% |
| Return on equity TTM | -47.61% |
| Profit margin | 0% |
| Book value | $0.74 |
| Market Capitalization | $104.9 million |
TTM: trailing 12 months
We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.6466. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.